Overview

* Dyne Therapeutics ( DYN ) Q2 net loss widens

* Co extends cash runway into Q3 2027, supporting multiple clinical milestones

* Dyne strengthens financial position with public offering and loan facility

Outlook

* Dyne expects cash runway to extend into Q3 2027

* Company plans U.S. Accelerated Approval submissions in 2026

* Dyne anticipates DYNE-251 commercial launch in early 2027

* Company pursuing approval pathways outside U.S. for DYNE-101 and DYNE-251

Result Drivers

* R&D INVESTMENT - Increased R&D expenses were $99.2 million

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS Miss -$0.97 -$0.95

(15

Analysts

)

Q2 Net Beat -$110.86 -$112.60

Income mln mln (13

Analysts

)

Q2 Beat -$115.79 -$136.50

Operatin mln mln (13

g Income Analysts

)

Q2 Basic -$0.97

EPS

Q2 $115.79

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Dyne Therapeutics Inc ( DYN ) is $44.50, about 77.6% above its July 25 closing price of $9.95

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)